<SEC-DOCUMENT>0001178913-25-001807.txt : 20250515
<SEC-HEADER>0001178913-25-001807.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515080010
ACCESSION NUMBER:		0001178913-25-001807
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20250515
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		25948795

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2533206.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;">
          <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 14pt;">UNITED STATES</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif;">SECURITIES AND EXCHANGE COMMISSION</font><br>
            Washington, D.C. 20549</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>
            UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25;">For the month of May 2025</div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25;">Commission File Number 001-38807</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</font><br>
            (Translation of registrant&#8217;s name into English)</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7, Tel-Aviv, Israel</div>
          <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746;&#160; <font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"></font>Form 40-F &#9744;</div>
          <div style="line-height: 1.25;"><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div class="BRPFPageHeader">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">On May 15, 2025, Chemomab Therapeutics Ltd. (the &#8220;Registrant&#8221;) issued a press release titled &#8220;Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate
            Update&#8221;, a copy of which is furnished as Exhibit 99.1 herewith. This Report on Form 6-K and the press release attached as Exhibit 99.1 to this Report on Form 6-K are hereby incorporated by reference into the Registrant&#8217;s Registration Statements
            on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).</div>
          <div style="line-height: 1.25;"><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div class="BRPFPageHeader">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0c37ae51feba4558904df6aca9367934">

              <tr>
                <td style="width: 6.82%; vertical-align: top;">
                  <div style="line-height: 1.25;"><u>Exhibit</u></div>
                </td>
                <td style="width: 93.18%; vertical-align: top;">
                  <div style="line-height: 1.25;"><u>Description</u></div>
                </td>
              </tr>
              <tr>
                <td style="width: 6.82%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 93.18%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 6.82%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">99.1</a></div>
                </td>
                <td style="width: 93.18%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Press release, dated May 15, 2025, titled &#8220;Chemomab Therapeutics Announces First Quarter 2025 Financial
                      Results and Provides Corporate Update&#8221;</a></div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div class="BRPFPageHeader">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="text-align: center; line-height: 1.25;">SIGNATURE</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
            authorized.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd39ff265f1fc4242994ba8918100fc47">

              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 45%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">Date: May 15, 2025</div>
                </td>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">By:</div>
                </td>
                <td nowrap="nowrap" style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="line-height: 1.25;">/s/ Sigal Fattal</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td nowrap="nowrap" style="width: 45%; vertical-align: bottom;">
                  <div style="line-height: 1.25;">Sigal Fattal</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 45%; vertical-align: top;">
                  <div style="line-height: 1.25;">Chief Financial Officer</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><img width="624" height="15" src="image3.jpg"></div>
        </div>
      </div>
      <br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
      </div>
      <br>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><img width="189" height="53" src="image0.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;"> Corporate Update</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8212;Reported Positive 48-Week Data from SPRING Trial&#8212;Nebokitug Treatment in PSC Patients with </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">of Liver Injury, Inflammation and Fibrosis&#8212;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8212;Aligned with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with&#160; </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">a Single, Clinical-Events-Driven Clinical Trial&#8212;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8212;These Major Milestones Support the Advancement of Nebokitug to Phase 3 and Position It to </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Potentially Become the First FDA-Approved Treatment for PSC&#8212;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#160;&#8212;Cash Runway Extended to the Second Quarter of 2026&#8212;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8212;Company Advancing Multiple Partnering Options for Executing the Nebokitug Program&#8212;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">TEL AVIV, Israel, May 15, 2025 </font>--
        <u>Chemomab Therapeutics Ltd</u>. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating
        results for the first quarter ended March 31, 2025, and provided a corporate update.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">&#8220;In the first quarter of 2025 Chemomab continued to successfully deliver on its commitments, achieving two major milestones with
        transformative potential for both the company and&#160; the global primary sclerosing cholangitis (PSC) community, &#8221; said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. &#8220;The first was achieving, for the first
        time, a clear regulatory pathway with the FDA to advance nebokitug to a potential full regulatory approval in PSC. The second was release of our positive 48-week Open Label Extension (OLE) data from the nebokitug Phase 2 SPRING trial&#8212;data that
        confirmed and extended the positive results seen in the 15-week placebo-controlled portion of the study.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Dr. Mor continued, &#8220;Earlier this year we reported the results of our End-of-Phase 2 meeting with FDA. We aligned on a full regulatory
        approval program for nebokitug using a single pivotal Phase 3 trial based on well-characterized clinical events that are associated with disease progression in PSC. Neither liver biopsies nor confirmatory studies are needed. We believe the use of a
        clinical event-driven endpoint derisks the Phase 3 trial, since data from the SPRING study showed that PSC patients with moderate/advanced disease treated with nebokitug for 48 weeks showed a significantly lower number of clinical events compared
        to historical controls. The OLE data also showed that nebokitug continued to be safe and well-tolerated over 12 months of treatment and resulted in broad and substantial improvements in all the key biomarkers associated with PSC. The results were
        especially strong in the 20 mg/kg dose that we intend to use in a Phase 3 trial, as well as in patients with moderate/advanced disease, a group that is most at risk for disease progression and that will be enrolled in Phase 3. Based on these
        developments&#8212;the strong 48-week SPRING trial data and the regulatory clarity achieved with the FDA<font style="font-style: italic;">&#8212;</font>nebokitug is positioned to potentially become
        the first FDA-approved treatment for PSC, a devastating disease with no FDA-approved therapies.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Dr. Mor added, &#8220;We plan to advance the Phase 3 program by collaborating with a strategic partner. We are in active discussions with a
        variety of potential strategic partners on multiple possible paths forward and are actively considering a variety of value-creating options for advancing nebokitug toward registration. We expect to report more detail on our plans in the coming
        months. I want to thank our talented and committed employees and collaborators, and the many PSC community members who contributed to our success in achieving these major milestones. We look forward to continuing to work together to progress
        nebokitug towards becoming the first FDA-approved therapy for this devastating disease.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">First Quarter 2025 and Recent Highlights:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z183f20d779e349e596a1110f1764c734" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On May 5, 2025, Chemomab announced that data from the company&#8217;s Phase 2 SPRING trial of nebokitug in PSC was presented in an oral Distinguished Abstract Plenary
                session at Digestive Disease Week&#174; (DDW 2025) in San Diego, California. The DDW 2025 session presented data from the double-blind, placebo-controlled 15-week treatment period and the 48-week open label extension portion of the study.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="ze00cb3718e40460c847d1fe370a0af4f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On April 28, 2025 Chemomab reported data from two study abstracts that were presented as posters at EASL 2025, the Annual Congress of the European Association for the
                Study of the Liver. In one study, comprehensive proteomic analyses of 3,000 circulating proteins in patient samples from the Phase 2 SPRING trial showed that nebokitug-treated patients exhibited significant and dose-dependent changes in
                proteins playing a key role in fibrosis, immune cell recruitment and inflammation.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>Nebokitug-treated patients showed reductions in multiple proteins, including those involved in downregulation of biological processes related to
                fibrosis and inflammation. The authors highlighted how nebokitug&#8217;s ability to neutralize CCL24 exerts a wide impact, including reductions in a broad array of inflammatory and fibrotic biomarkers in treated patients. The second study
                analyzed the pharmacodynamics and pharmacokinetics (PK) of nebokitug and CCL24 using data from the SPRING trial. PK analyses indicated effective antibody-target engagement, and linear regression analyses found trends between increasing
                patient exposure to nebokitug and decreasing&#160; levels of PSC disease biomarkers.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z465d6495af224bbdaccb9cecab12c3de" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On April 15, 2025, Chemomab announced new medical and clinical appointments. David M. Weiner, MD, rejoined Chemomab as Interim Chief Medical Officer, binging
                extensive biotechnology and pharmaceutical industry R&amp;D, drug development and strategic experience, and Jack Lawler, who oversaw the conduct of Chemomab&#8217;s successful Phase 2 SPRING Trial in PSC, was promoted to the position of Chief
                Development Officer.&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zd01cf49143934c28b0003244f1de7e05" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On March 27, 2025, Chemomab announced positive results from the Open Label Extension (OLE) portion of the Phase 2 SPRING trial of nebokitug in PSC. The OLE study
                confirmed that the drug was safe and well-tolerated in PSC patients for up to 48 weeks and resulted in positive effects, including continued improvements in key liver biomarkers such as the ELF score, the fibrosis-related components of ELF
                and the fibrosis biomarker PRO-C3. Liver stiffness scores as measured by FibroScan&#174; were substantially lower in the nebokitug-treated patients with moderate/advanced disease compared to historical controls. Cholestasis-related markers
                stabilized over 48 weeks of treatment and total serum bile acids were reduced. Importantly, OLE patients with moderate/advanced disease treated with nebokitug for 48 weeks showed a significantly lower number of clinical events compared to
                historical controls.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z7360ee6d39424bd3bce837a28abd46e7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On&#160; March 6, 2025, Chemomab announced a new scientific presentation at the 8th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 2025)
                that further confirmed the potential of nebokitug as a novel treatment for systemic sclerosis. The new data added to the extensive body of preclinical evidence that CCL24 is a key driver of the skin, lung and vascular manifestations of this
                disabling condition that lacks disease-modifying therapies.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z7cc7a338663a4bb6a3f10136fec67d70" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On February 19, 2025, Chemomab announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) and alignment with
                FDA on the design of a Phase 3 registration study for nebokitug for the treatment of PSC. The design provides clarity on a streamlined path to full regulatory approval based on a single pivotal trial that does not require liver biopsies or
                confirmatory studies. The primary endpoint measures time-to-first clinical event and encompasses multiple clinical events associated with disease progression. Key publications have shown that the reductions in PSC biomarkers seen in the
                nebokitug Phase 2 SPRING trial are associated with reductions in clinical events, increasing&#160; confidence in the relevance of this approach for the nebokitug Phase 3 trial.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z7bd75d895818433c9226008a3f44f82f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On February 19, 2025, Chemomab reported that the International Nonproprietary Names (INN) program of the World Health Organization had assigned the INN designation
                nebokitug to the company&#8217;s lead product candidate CM-101.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z3d15f6387d5e4f58af86e0521ce02763" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>On January 13, 2025, a new peer-reviewed publication in the journal <font style="font-style: italic;">Cells</font>
                further confirmed the key role of the soluble protein CCL24 in driving the fibro-inflammatory pathologies underlying PSC, systemic sclerosis and other fibrotic diseases<font style="font-style: italic;">.</font> The review describes the pivotal role CCL24 plays in initiating and advancing fibrotic processes, highlighting its impact on fibrotic, immune and vascular pathways. It also presented preclinical and
                clinical evidence supporting the therapeutic potential of blocking CCL24 in diseases that involve excessive inflammation and fibrosis.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">First Quarter 2025 Financial Highlights</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zee4adc11f73d403e9d51a288d0347bf1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9726;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">Cash Position:&#160;</font>Cash, cash equivalents and short-term bank
                deposits were $10.6 million as of March 31, 2025, compared to $14.3 million as of December 31, 2024.&#160; This cash runway is expected to fund the company through the second quarter of 2026.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zf5ef9843db22486682973c36c1d5b36e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9726;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">Research and Development (R&amp;D) Expenses: </font>R&amp;D expenses
                were $2.5 million for the first quarter of 2025, compared to $3.1 million for the first quarter of 2024. The decrease in R&amp;D expenses in the first quarter of 2025 compared to the first quarter of 2024 primarily resulted from the
                continued winding down of activities related to the Phase 2 SPRING trial .</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z3990cfe3955448b389616ea9433d4d5d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9726;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">General and Administrative (G&amp;A) Expenses</font>: G&amp;A expenses were $1.0 million for the first quarter of 2025, compared to
                  $0.9 million for the first quarter of 2024. The increase in G&amp;A expenses primarily reflects increases in share-based expenses.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z560603a138aa494f831c1a0f5b6e19ea" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9726;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">Net Loss</font>: Net loss was $3.3 million, or a net loss of less than
                $0.01 per basic and diluted ordinary share for the first quarter of 2025, compared to $3.9 million, or a net loss of less than $0.01 per basic and diluted ordinary share for the first quarter of 2024. The weighted average number of ordinary
                shares outstanding, basic and diluted, was 456,149,916 (equal to approximately 22.8 million ADSs) for the first quarter of 2025.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z7b41df7838ea4feaa8f5c00194726ac9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9726;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">Liquidity and Capital Resources</font>: Chemomab believes its existing
                liquidity resources as of March 31, 2025 will enable it to fund its operations through the second quarter of 2026.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z220417ccde4c497a8a870a0a211364c2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9726;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">Number of Issued and Outstanding Shares</font>:<font style="font-weight: bold;">&#160;</font>As of March 31, 2025, the company had 377,256,460 Ordinary shares issued and outstanding (equal to 18,862,823 ADSs), compared to 377,132,220 (equal to
                18,856,611 ADSs) as of December 31, 2024.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statements</div>
      <div style="line-height: 1.25;">This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities
        Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of
        operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology
        such as &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events
        and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other
        things: the risk that certain acknowledgements from the End-of-Phase 2 (EOP2) meeting with the FDA in connection with PSC regulatory approval will not materialize into a pathway for regulatory approval; that certain conclusions and assumptions
        drawn from the EOP2 meeting with the FDA discussed in the press release will prove incorrect and adversely affect the ability for nebokitug to become an FDA fully approved therapy; the risk that the full data set from the nebokitug study or data
        generated in further clinical trials of nebokitug will not be consistent with the topline results of the nebokitug Phase 2 PSC trial; failure to obtain, or delays in obtaining, regulatory approvals for nebokitug in the U.S., Europe or other
        territories; failure to successfully commercialize nebokitug, if approved by applicable regulatory authorities, in the U.S., Europe or other territories, or to maintain U.S., European or other territory regulatory approval for nebokitug if
        approved; uncertainties in the degree of market acceptance of nebokitug by physicians, patients, third-party payors and others in the healthcare community; nebokitug development of unexpected safety or efficacy concerns related to nebokitug;
        failure to successfully conduct future clinical trials for nebokitug, including due to the Company's potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval,
        among other things; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient quantities
        of nebokitug for commercial or clinical needs, to conduct the Company's clinical trials; changes in laws and regulations applicable to the Company's business and failure to comply with such laws and regulations; business or economic disruptions due
        to catastrophes or other events, including natural disasters or public health crises; and uncertainties with respect to the Company's need and ability to access future capital; and the intensity and duration of the current war in Israel, and its
        impact on our operations in Israel. These risks are not exhaustive. You should carefully consider the risks and uncertainties described in the &#8220;Risk Factors&#8221; sections of our 20-F for the year ended December 31, 2024. New risk factors emerge from
        time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
        materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Except as required by law, we undertake no obligation to update publicly any
        forward-looking statements for any reason after the date of this press release. Before you invest, you should read the documents we have filed and will file with the SEC for more complete information about us. You may get these documents for free
        by visiting EDGAR on the SEC website at <u>www.sec.gov</u>. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these
        securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities law of any such state or jurisdiction.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25;">Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet
        need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated
        disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory
        diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of
        a nebokitug PSC Phase 3 trial. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory approval. Nebokitug has received FDA and EMA
        Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab&#8217;s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit: <u>chemomab.com</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-weight: bold;">Contacts:</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Media &amp; Investors:</div>
      <div style="line-height: 1.25;">Chemomab Therapeutics:<br>
        Barbara Lindheim<br>
        Consulting Vice President<br>
        Investor &amp; Public Relations,</div>
      <div style="line-height: 1.25;">Strategic Communications</div>
      <div style="line-height: 1.25;">Phone: +1 917-355-9234</div>
      <div style="line-height: 1.25;"><u>barbara.lindheim@chemomab.com </u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: right; line-height: 1.25;">Chemomab Therapeutics Ltd. and its subsidiaries</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><font style="font-weight: bold;">Interim</font>&#160;<font style="font-weight: bold;">Condensed Consolidated Balance Sheets (Unaudited)</font>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="line-height: 1.25;">In USD thousands (except for share amounts)</div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zc69f90743fe44fdc86dc9c47bd48e713" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">March 31,
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2025</div>
                </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">December 31,</div>
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25; font-weight: bold;">2024</div>
                </div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Cash and cash equivalents</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">8,338</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">6,071</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Short term bank deposits</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">2,225</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">8,195</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Restricted cash</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">140</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">76</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Other receivables and prepaid expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">1,274</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">1,698</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">11,977</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">16,040</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Non-current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Long term prepaid expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">341</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">385</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Property and equipment, net</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">237</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">250</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Operating lease right-of-use assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">264</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">289</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total non-current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">842</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">924</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
              <div style="line-height: 1.25; font-weight: bold;">Total assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">12,819</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">16,964</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">Current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Trade payables</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">490</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">666</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Accrued expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">1,365</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,563</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Employee and related expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">279</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">874</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Operating lease liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">113</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">115</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">2,247</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">3,218</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">Non-current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Operating lease liabilities - long term</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">179</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">209</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total non-current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">179</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">209</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Commitments and contingent liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">2,426</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">3,427</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Shareholders' equity (*)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 76%;"><br>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Ordinary shares no par value - Authorized: 4,650,000,000 shares as of March 31, 2025, and as of December 31, 2024;</div>
              <div style="line-height: 1.25;">Issued and outstanding: 377,256,460 Ordinary shares as of March 31, 2025 and 377,132,220 as of December 31, 2024;</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Additional paid in capital</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">116,339</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">116,160</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Accumulated deficit</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">(105,946</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">)</div>
              </div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">(102,623</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">)</div>
              </div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total shareholders&#8217; equity</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">10,393</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">13,537</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total liabilities and shareholders&#8217; equity</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">12,819</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">16,964</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">The accompanying notes are an integral part of the interim condensed consolidated financial statements&#160; &#160; &#160; &#160; &#160;</div>
      <div style="line-height: 1.25;">(*)&#160; 1 American Depositary Share (ADS) represents 20 Ordinary Shares</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: right; line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
      <div style="text-align: right; line-height: 1.25;">and its subsidiaries</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-weight: bold;">Interim Condensed Consolidated Statements of Operations (Unaudited)
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="line-height: 1.25;">In USD thousands (except for share and per share amounts)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zb0e3a3e689434397b7442a4d8259b48f" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">Three months</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">Three months</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">Ended</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">
              <div style="text-align: right; line-height: 1.25; font-weight: bold;">Ended</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">
              <div style="text-align: right; line-height: 1.25;"><font style="font-weight: bold;">March 31</font>,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">
              <div style="text-align: right; line-height: 1.25;"><font style="font-weight: bold;">March 31</font>,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="line-height: 1.25;">
                <div style="text-align: right; line-height: 1.25; font-weight: bold;"> 2025</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="line-height: 1.25;">
                <div style="text-align: right; line-height: 1.25; font-weight: bold;">2024</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Operating expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Research and development</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">2,493</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,152</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">General and administrative</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">994</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">896</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total operating expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">3,487</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">4,048</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Financing income, net</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">164</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">180</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Net loss for the period</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">3,323</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">3,868</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z44d5fa8da7174a928439d9b494920dbe" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Basic and diluted loss per Ordinary Share (*)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25; font-weight: bold;">0.007</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">0.014</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" rowspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" rowspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Weighted average number of Ordinary Shares outstanding, basic, and diluted (*)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">456,149,916</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">284,151,752</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The accompanying notes are an integral part of the interim condensed consolidated financial statements.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(*)&#160; 1 American Depositary Share (ADS) represents 20 Ordinary Shares</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !S 98# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]F3XR>$OBIIN@7,%EXDM-$O&36_#5W=1>=:V^O:'=I!J6FM<P_O+:6:W^SW
M#"&9V1U7ZJK_ #AO^#33PM\8KW_@H+XX\6>$;;7HOA)HOP-\4:9\5-2C%XOA
M6:_U+6O#DG@S2;_:ZV$_B%[NWU*]T;S4FNK2P@UDPF"*[E\[_1YI<?<,8;A#
MB3$Y+A,=+'T*5'#5XU*B@J]+ZQ34_88A4_<]K#XDTH<U*=.;A'FL'#^:5<XR
MRECJN'^KSG.I!P7,X2]G+E]I3<E=PEMK>TE)7=KA1117Q9[04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%<EXV\>^"OAMX?O?%?C_Q3H7@_PYIZ
M-)=ZSX@U*VTRQB"(TA437,B"278C,L,0DF958JAP:^9M&_X* _L<:]K$&AZ?
M\?/!'V^[N8[2T-Y<7NGVES<32+%#'%?WUG;V8,LCJD;2S1HS$*&R0#]#E7"/
M%>>X3$8_).&>(,XP.$<EBL9E>39CF&%P[C%3E&MB,+AZM*E*,&IRC.:<8^\T
MHZG/5QF$H3C3KXK#T9RUC"K6ITYRN[+EC.2;N]-$]=#Z*^)_PV\)_%_P!XJ^
M&OCG3AJ?A;QAI%SH^K6P=HIEBG7]W=6=POSVU]93K%=V5S'\\%S#%(,[<'^5
MG]H+_@D+^TQ\-/$M\?A;HC?&+P3/>2?V+J.A7&G6OB*&S=F>*+7-#O;JS\FZ
MMXBD<]Q8/<6=S*&DMTA4B!/ZVK6[M;^V@O;&YM[RSNHDGM;NUFCN+:Y@E4/'
M-!/"SQ312*0R21NR.I!4D'-6*_3?"#Q[X^\%,1F$.&JF!QF5YE4A5S'(,[H5
MZ^75,71C[..+I+#XC"8O!XR-->QJ5*&(A&O3C"&)IUO8T'2\K.>'\OSV-/ZV
MJD*M)-4L10E&-6,).[@^:,X3@WJE*+Y6VXM<TK_R4?L[_P#!(']I#XD>)=.F
M^+>D?\*?\#6]XAUJZUBZT^[\47-K$Z-)!HFBV4]ZC7%U%O2&[U&6"TMG*R2Q
M7.TV[?U0?#CX=^$?A/X(\-_#SP+I$&B>%O"NF6VE:58P*N?*MXU1KFZE"JUS
M?7<@:YO;N3,ES<R22N<M@=O7Y1_\%!O^"D^B_LL!OAK\-K73O%?QIO[-;B=;
MLBZT+P-;W,8:SGUJV@E26^U:Y5DN+71A+!LMBMS>RQ)/:QW'UG$W'_C']*_B
MO)>%J.#PM9T)5J^7\/Y-3JX'(\MBU&&+SK-,1BL1B:C5"E*-.6,QF(J*C"?U
M? T8UL5*EB.3"Y=DG"&#KXISG%2Y8U<37:J5ZNON4:<81BG=ZJ%."N_>F[1O
M']#OB?\ !?X4?&C2H-$^*WP_\+^/-,M93-:0>(M+@O7LY3C>]E=,JW=H9, 2
MBVGB$H $@8  :_@#X:^ /A5X?A\+?#?P?X?\%>'H',B:5X=TRVTVV>8@*9YQ
M BO=7#*JJUQ<O+.RJJF0A0!_*=X=\,_\%2/VR!;_ ! TO5_BQ<>&[\SOIFM'
MQ0_P^\*O;S%+F$:586^H:)'J-D8Y$2RU"ST^_A\M&1KW>7WLU+Q1_P %.OV$
M[R'Q1XLU'XDVWA8W\2S7'BC56^(O@/4F79%%;7LLNHZO'I<%Q-.D44+7&B75
MW<#$)8D,WZ)+Z+.;5\&N!\-](#@#&\14*TJM/P[7$&*^IQS5.7M*%&A]<J3C
MF&DDW_8,,1S-^TC"G>H>;_K92C-X^?#N9T\+**3S+ZM'G]C9-2D^5+V75?OW
M&UK-O0_KKKQ[XU?L^? _]H[PK_PA'QW^%/@;XL>%!,;B+1?''A[3]=M;:X*&
M-KBR:[A>>QG>)FBDELYH))(F:)V:-BI^=?V#/VT]*_;+^'&KZW)X?D\+^-_!
M%WINE^,])C<W&DS2ZI!<S:=J^B73'S397XL;V.2SN@MS97-K-&6GMWM[B;[K
MK^1.)N&N(.!>),RX:X@PE7*<_P CQ2H8S#JK"4Z-5TX5Z-6CB,/.5.I2K4*M
M+$8>O1J2A5HU:=2$K21]CA<3A\?A:6)P\XUL-B(<T)6=I1=TU*,E=--.,HR5
MU).+5T>1?!CX!_!7]G7PE'X$^!?PN\$?"GPA'+]H.@^"/#]AH5E-<;!&+B[%
MG$DM[<+&JQ)/>2SRI$JQ*XC55'KM%%?/SJ3JSE4J3G4J3DY3G.3G.<GJY2E)
MN4I-ZMMMLZ$E%)1222LDE9)+9)+1(***\,_:3_:,^$_[)WP5\>?'WXV>);?P
MK\._AYHUQJ^LZA*#+=73HI%EI&D64>;C4];U>Z\NQTK3;5)+F]NYHX88V8TZ
M5*K7JTZ-&G.K6K3A2I4J<93J5*E22C"G"$4Y3G.348QBFY-I)782E&$93G)1
MA%.4I2:C&,8J\I2D[)))-MMV2U9[G7*W?COP1I]PUI?^,O"ME=(=KVUWXATB
MVN%.<8:&:\213D$8*@YXZU_!SX@_;R_X+#?\%[OBUXK^&O[!EIK_ .S%^RQX
M>OY-)UWQ'IVO2^$8[&QFD@O=/NOB/\5]+MKC7G\67%E:PW,7@WX;S 6']K-;
M:K<:AI5W9ZJOT7I'_!H=JWBVWU+Q+\<_V[/$WB[XF:X%N]2UW3O!<UZDNH&V
M2)1JNH^*_$&NZYKCVPCAMS>R7UH\\$*JD,"[%3]%J<"Y3DRA2XPXNP>19E.$
M:DLGP&7XC/LPPBFHRC',/JU7#X7"5'3E[3V?UFI/DE3<8SYI<GSL<\Q>-O/)
M\HK8_#*3BL;B,33R_#5N5VD\-[2%6O6BG>*G[&$.:,_>TCS?VN6=[9ZA EU8
M7=M?6LG^KN;.>*Y@?_<FA=XVZC[K&IWD2)'DD8)'&K.[L<*B("S,Q/ "J"23
MT K^$3X@_P#!+7_@N%_P22LO^%Q_L1_M6^*?VE?ACX%L([_7/AAI#:_?W<?A
MG1;C^TI]&@^!_BO4O%6DZ]I?]FV36NH'P%?Z9XON(9#9>'+$74T C_L\^!7B
M?XI^-?V9?AKXP^-VA:%X8^+GBCX2Z+K_ ,0O#WAE[^30M'\3ZMX=2^U*PTTZ
MG#;Z@L$$L^PQWD$,\,OF1/$A3:/GL^X>P>54<'C<MXARO/\ +\;5K4:57">W
MPV-H5*$:4JD,;EN+A#$8:ZJQ=.=ZE.HKM35TGZ& S"MBIUJ&)R_%X#$4(PE.
M-;V=6A4C4<U&6'Q5&<Z57X'SQ]R<'HX]3KO 7QQ^#GQ3U/6-%^&WQ/\  WCK
M5_#RA]=TSPKXETK7+[1U-S-9AM2MM/N9Y;,&ZMY[<>>J9FAEC'S(P'J=?Q%_
M\&N0 _;I_P""J(  "Z]HRJ ,!5_X6M\7!@ =!@ 8'& /05_;I67%F0QX:SO$
M91#$RQD:.&R[$*O*DJ+E]?R["X]P]FJE1+V3Q/LE+G?.H<]H\W*JRK'O,L%3
MQCI>Q<ZN)I^S4_:6^KXFMA^;FY(?'[+GMR^[S<MY6YF4445\X>B%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116=J.KZ3H\(N-7
MU/3M+@8[5GU&]MK&$M_=$ES+$A/L&S1J]$KL#1HJAIVJZ9J\'VK2=1L-4ML[
M?M&G7EO>P;AU'G6TDL>1@\;L\5?H *\HT3X[?!?Q)XZO_AAX?^*?@/6OB+I<
MVIV^I>!],\3Z3>>*;"?1B1JT5WHD%T^H6[Z:01>K+ IMSQ)M->KU_"Q_P3:
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MX:L_$/BJSM[VYABU6#Q#XJOQ<:K=7-L(#._A[P_)X7M+N*Y@M-<U C(^)/\
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M!%IE_9W&F)=ZQMM[OPU=W5VMM>Q2W=B\VF2V=U<?Z4%?P1_\'='[(O@OP/\
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MUM;6_B&SLKKXC7GB'2)GL'O[O1_^$'T6SO[U[&35-3M87@_H^_X*?6%]>_\
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M24X27L*.L91;37FF8\+QE#A_*H3C*$HX9*491<9)\\]&G9I^J/X2_P#@D_\
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MJ'<P@&W\P/%?A?\ X*J_\')/Q?\  MCXY^&>N?LF?L&>#-;CUY+O5],U;2M
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M-5T[X,>'+2_TS5+.YT_4+&Z@C>.:VO+*[CAN;:>)U*2131)(C AE!IUJD/\
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ME9J$HSYW;E?^A?1117XR?9A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4A( ))  &23P !U))Z 4M(0&!4@$$$$$9!!X((]"* .7
MC\<^"IKA+6+QAX6ENI)OL\=M'X@TE[B2X+;! D*W9D:8O\GE*I?=\NW/%=#<
M7=K:>3]JN;>V^T3QVMO]HFCA\^YE#&*WA\QE\V>0(QCA3=(X5MJG!KXN\/\
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8DVY2;;;YGJV]6SK@K0@DK)1C9)66R/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2P!W\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
